lol--
Vermectin had no clinical benefit against COVID-19 in largest study to date - WSJ
Mar. 18, 2022 11:18 AM ETMerck & Co., Inc. (MRK), PFE
Poor Joe Rogan!
A group of researchers evaluating the effect of repurposed drugs against COVID-19 found that oral antiparasitic medication ivermectin did not improve patient outcomes in the largest trial of its kind to date, The Wall Street Journal reported on Friday.
Ivermectin marketed by Merck (NYSE:MRK) as Stromectol for parasitic infestations sparked controversy during the pandemic prompting the U.S. Food and Drug Administration (FDA) to issue warnings against its excessive use.
“There was no indication that ivermectin is clinically useful,” said Edward Mills, a lead investigator of the trial and a professor of health sciences at Canada’s McMaster University in Hamilton, Ontario.
Vermectin had no clinical benefit against COVID-19 in largest study to date - WSJ
Mar. 18, 2022 11:18 AM ETMerck & Co., Inc. (MRK), PFE
Poor Joe Rogan!
A group of researchers evaluating the effect of repurposed drugs against COVID-19 found that oral antiparasitic medication ivermectin did not improve patient outcomes in the largest trial of its kind to date, The Wall Street Journal reported on Friday.
Ivermectin marketed by Merck (NYSE:MRK) as Stromectol for parasitic infestations sparked controversy during the pandemic prompting the U.S. Food and Drug Administration (FDA) to issue warnings against its excessive use.
“There was no indication that ivermectin is clinically useful,” said Edward Mills, a lead investigator of the trial and a professor of health sciences at Canada’s McMaster University in Hamilton, Ontario.
